Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 7.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,501,654 shares of the medical equipment provider’s stock after selling 262,266 shares during the quarter. Van ECK Associates Corp’s holdings in Zimmer Biomet were worth $301,457,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of ZBH. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet during the second quarter worth $1,344,282,000. Primecap Management Co. CA acquired a new position in Zimmer Biomet during the second quarter worth approximately $328,578,000. Norges Bank purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $221,234,000. Bank of America Corp DE acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $187,480,000. Finally, Franklin Resources Inc. boosted its holdings in shares of Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Get Zimmer Biomet alerts:

Zimmer Biomet Stock Performance

Shares of ZBH opened at $101.10 on Friday. The firm has a market cap of $19.28 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.70 and a beta of 0.45. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $93.88 and its two-hundred day moving average is $91.45. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $106.88.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the firm earned $2.07 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZBH. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $96.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Citigroup decreased their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Finally, Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $104.42.

Check Out Our Latest Stock Report on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

See Also

• Five stocks we like better than Zimmer Biomet
• MarketBeat Week in Review – 08/24 – 08/28
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.